D.A. Davidson & CO. Sells 7,789 Shares of DexCom, Inc. (NASDAQ:DXCM)

D.A. Davidson & CO. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 24,789 shares of the medical device company’s stock after selling 7,789 shares during the period. D.A. Davidson & CO.’s holdings in DexCom were worth $1,928,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Principal Securities Inc. increased its holdings in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after purchasing an additional 185 shares in the last quarter. Peterson Wealth Services boosted its stake in shares of DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after buying an additional 201 shares during the last quarter. Finally, Magnolia Capital Advisors LLC boosted its stake in shares of DexCom by 2.6% during the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock worth $638,000 after buying an additional 210 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 over the last three months. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DXCM. Morgan Stanley increased their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup increased their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Trading Down 0.6 %

Shares of DXCM stock opened at $88.78 on Friday. The firm has a 50 day moving average price of $83.50 and a two-hundred day moving average price of $76.06. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $34.69 billion, a PE ratio of 62.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.